Long-term clinical outcomes in large colorectal polyps with indefinite or positive resection margin after endoscopic resection

Abstract

is a curative treatment for colon cancer (CC), recurrence adjuvant chemotherapy (AC) in stage II CC is controversial.have been associated with poor prognostic outcomes and in the decision making algorithm for stage II CC. d an unicentric retrospective study. Patients with resected stage 2014 were identified. Univariate analysis were performed for (CRF), and those which obtained a p < 0.05 were incorporatedIn addition, we analyzed the relapse free survival (RFS) and according to the presence of at least one risk factor. Finally, AC in patients depending on the presence or absence of risk was employed for the analysis.identified. 60% were men. Median age at diagnosis was 74 sided (55%) and stage IIA (86%). 62% had at least one CRF. AC, most of them having at least one risk factor (82%). months. Median 5-year RFS was 67,3% and the 5-year OS ariate analysis for OS: T stage, the presence of perforation or margins were significant prognostic factors (HR 2.1, 2.3, 2.8 the multivariate model: obstruction, perforation and positive risk factors for OS (HR 3.1, 1.9 and 3.2 respectively). The performed: T stage, lymphovascular infiltration, perforation margins and presurgical CEA elevation were significant risk analysis (HR 2.1, 2, 2.1, 2.6, 2.3 and 2.4, respectively). and lymphovascular infiltration were the only prognostic model (HR 3.6 and 4.6, respectively). Having at least one factor for OS (HR 1.9, p ¼ 0,015) and RFS (HR 2.2, risk factors identified in our analysis, similar results were p < 0.001) and RFS (HR 1.8, p ¼ 0.008). In addition, patients AC had benefit in OS (HR 0.27, p < 0.001) and RFS there was not benefit in patients without any CRF neither for ifying patients only according to risk factors identified in our accurately which patients benefit from AC. selection of patients with stage II colon cancer who can benefit avoid overtreatment and for improve prognosis of those In this way, CRF seems to stratify properly patients who benewho need closer surveillance. However, more precise informamolecular biomarkers could help to accurate decision .Multicenter phase Ib/II study of nivolumab monotherapy nt radical surgery following preoperative (CRT) with capecitabine in patients with locally rectal cancer (LARC)